1997
DOI: 10.1590/s0037-86821997000200009
|View full text |Cite
|
Sign up to set email alerts
|

Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crônica da doença de Chagas, em uma área de campo com transmissão interrompida. I. Avaliação preliminar

Abstract: São poucos os estudos controlados sobre a terapêutica específica da doença de Chagas crônica, particularmente em áreas de campo, onde o acompanhamento dos pacientes tornase mais difícil, por falta de condições laboratoriais e de profissionais capacitados para fazê-lo adequadamente.Alguns estudos sobre tolerância e eficácia do nifurtimox e do benznidazole em pacientes nas fases aguda e crônica da doença de Chagas foram realizados no Brasil e em outros países do nosso continente 6 7 12 13 15 16 17 20 21 28 29 30… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
59
0
18

Year Published

1999
1999
2020
2020

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 81 publications
(77 citation statements)
references
References 12 publications
0
59
0
18
Order By: Relevance
“…In Brazil, Fragata Filho et al (1995) conducted a retrospective study that found that among 61% of subjects with negative xenodiagnosis, only 7% of treated patients (both cured and uncured) experienced worsened clinical states opposed to 14.3% of the placebo group, after seven years of follow-up. In 1997, Coura et al (1997). Treated 26 chronic chagasic patients who had at least two positive results out of three xenodiagnosis tests and verified that after one year, only 1.8% continued to have positive xenodiagnosis even though serologic tests remained positive.…”
mentioning
confidence: 94%
“…In Brazil, Fragata Filho et al (1995) conducted a retrospective study that found that among 61% of subjects with negative xenodiagnosis, only 7% of treated patients (both cured and uncured) experienced worsened clinical states opposed to 14.3% of the placebo group, after seven years of follow-up. In 1997, Coura et al (1997). Treated 26 chronic chagasic patients who had at least two positive results out of three xenodiagnosis tests and verified that after one year, only 1.8% continued to have positive xenodiagnosis even though serologic tests remained positive.…”
mentioning
confidence: 94%
“…[5][6][7] Nevertheless, nitroderivative compounds with anti-trypanosomal activity have been used to treat T. cruzi infections in humans. [8][9][10][11][12][13][14] Benznidazole (N-benzyl-2-nitro-imidazoleacetamide) and nifurtimox (4-[5-nitro-3-methyl-furphurylideneamino]-tetrahydro-4-H-1, 4-thiazine-1-1-dioxide) curtail parasitemias and are indicated for treating acute Chagas disease. [9][10][11] However, these drugs cannot be administered without the supervision of a physician because they provoke undesirable side effects.…”
Section: Introductionmentioning
confidence: 99%
“…[9][10][11] However, these drugs cannot be administered without the supervision of a physician because they provoke undesirable side effects. 12,[15][16][17] In addition, their efficacy for treating chronic Chagas disease has yet to be determined.…”
Section: Introductionmentioning
confidence: 99%
“…In addition to the lower efficacy of chemotherapy applied to chronic infection, the belief that autoimmune events play an important underlying role in Chagas pathogenesis, even after the post-therapeutic parasite clearance (Coura et al 1997), has led several investigators to conclude that it is not worth treating chronic Chagas disease patients (CD). However, a few follow-up studies on treated CD have pointed out that, in fact, despite the autoimmune mechanisms triggered by T. cruzi infection, most tissue damage is indeed dependent on the presence of the parasite (Viotti et al 1994).…”
mentioning
confidence: 99%